Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78971 | 0.89 | F10 (0.67) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2233431 | 0.89 | F10 (0.67) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3276611 | 0.89 | F10 (0.67) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15203331 | 0.84 | F10 (0.47) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14838660 | 0.83 | F10 (0.49) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12869930 | 0.82 | F10 (0.58) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18843493 | 0.82 | F10 (0.58) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL80372 | 0.81 | F10 (0.66) | F10ABCB11F2ST14 | |
| SCHEMBL14838626 | 0.81 | F10 (0.67) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL17897808 | 0.80 | F10 (0.56) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106192-B2 | Method for producing 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20100081807-A1 | METHOD FOR PRODUCING 5-CLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE | BAYER HEALTHCARE AG (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20070149522-A1 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | BAYER HEALTHCARE AG (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149522-A1 | Method for producing 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide | NT5C, NOX5, MT-ND5 | F10 4544/4885CYP1A2 234/4885CYP3A4 339/4885 |
| US-20100081807-A1 | METHOD FOR PRODUCING 5-CLORO-N-(METHYL)-2-THIOPHENECARBOXAMIDE | CBR3, NT5C, CBR1 | F10 4090/4885CYP1A2 174/4885CYP3A4 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.